Q1 2026 PI Industries Ltd Earnings Call Transcript
Key Points
- PI Industries Ltd (BOM:523642) reported a strong performance in its Pharma business, showing an 86% year-on-year growth in revenue.
- The company has commercialized 15 new molecules over the last three years, with a 46% growth in new products year-on-year.
- PI Industries Ltd (BOM:523642) has a robust gross margin of 57.4%, an increase of 5.7% from the previous year.
- The company is making significant investments in technology and strategic partnerships to enhance its global presence and operational efficiency.
- PI Industries Ltd (BOM:523642) has a healthy net cash balance of INR41,005.54 million, indicating strong financial health.
- The company experienced an 8% decline in revenue compared to the same period last year, primarily due to macroeconomic headwinds and geopolitical uncertainties.
- There was a decline in the biological segment due to regulatory changes, impacting domestic growth.
- The trade working capital in terms of days of sales increased to 91 days from 73 days in March 2025, indicating potential inefficiencies in inventory management.
- The ag chem export side saw a decline in line with customer delivery schedules to balance inventory levels.
- The ongoing U.S. tariff situation creates uncertainty, which could impact future business operations.
Ladies and gentlemen, good day, and welcome to PI Industries Limited Q1 FY26 earnings conference call. (Operator Instructions) Please note that this conference has been recorded. I now hand the conference over to Siddharth from CDR India. Thank you, and over to you.
Thank you, Abhirath. Good afternoon, everyone, and thank you for joining us on PI Industries quarter one FY26 earnings conference call. Today, we are joined by senior members of the management team, including Mr. Mayank Singhal, Executive Vice Chairman and Managing Director; Mr. Rajnish Sarna, Joint Managing Director; Mr. Sanjay Agarwal, Group Chief Financial Officer; Dr. Atul Gupta, CEO, CSM AgChem; Mr. Prashant Hegde, CEO, AgChem Brands; Dr. Ramesh Subramanian, Global CEO of PI Health Sciences.
We will begin the call with key perspectives from Mr. Singhal, following which we will have Mr. Agarwal, sharing his views on the company's financial performance. Thereafter, the forum shall be open for a question-and-answer session.
Before we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
